Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NIVOPTIMIZE: Nivolumab dose optimization in responders with advanced melanoma or renal cell carcinoma
2021-001707-32Phase 4Active
- Sponsor
- Erasmus MC
- Start
- Apr 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of nivolumab in melanoma and renal cell carcinoma (RCC), sponsored by Erasmus MC. Primary endpoint: Primary: Difference in nivolumab trough levels. Started Apr 2021; status: active.
02
Drugs
03
Conditions
melanomarenal cell carcinoma (RCC)
Beyond the preview
Go deeper on 2021-001707-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001707-32.